Innovest Global Inc. Marks Its Fifth Acquisition of 2018 and Is Poised To Increase Its Annual Revenue to over Five-Times Its Current Rate with a Pending Acquisition of a $30 Million Revenue Company
Innovest Global Inc. (OTCMarkets:IVST) (the "Company" or "Innovest"), sales from its existing business units continue to grow, the Company now owns a 20% stake in StemVax Therapeutics, which has the worldwide exclusive rights to a brain cancer vaccine, which is patent protected. Innovest has announced a pending acquisition of a $30 million revenue company, which would mark its fifth acquisition of 2018, and increase the Company's annual revenue to over five-times its current rate.
View full press release